Neuralstem promotes Richard J. Daly to chairman
Mr. Daly has served as a director on Neuralstem’s board since February 2016, when he also assumed the chief executive role of Neuralstem, as President and CEO. His career of commercial pharmaceutical leadership experience spans over 25 years and encompasses strategy, sales, marketing, and operations.
Prior to joining the company, Mr. Daly served as Managing Director of Ravine Rock Partners, where his expertise was leveraged as the Interim CCO of Catalyst Pharma until September 2015.
Mr. Daly led the turnaround initiatives of Bristol-Myers Squibb – AstraZeneca Diabetes Alliance when serving as the President of the U.S. Diabetes subsidiary from 2013 through the AstraZeneca integration completion in 2014.
From 2011-2013, Mr. Daly was a founding Partner and Board member of SagePath Partners, a commercial outsourcing provider to the pharmaceutical industry which was sold to Ashfield Commercial & Medical Services in 2013.
He was also part of the executive leadership team that executed the formation and growth of Takeda North America.
During his 13-year tenure, Mr. Daly served as EVP, U.S., where he was responsible for new affiliates and business development for the Americas. Earlier in his career, he served as the VP of Commercial Strategy at TAP Pharmaceuticals, an Abbott Labs and Takeda joint-venture, and SVP of Marketing at Takeda North America.
Mr. Daly currently also serves on the boards of Catalyst Pharmaceuticals and Synergy Pharmaceuticals.
Mr. Daly earned an M.B.A. from Northwestern University’s Kellogg Graduate School of Management and holds a B.S. in Microbiology from The University of Notre Dame. ■
LATEST MOVES FROM Maryland
- Under Armour appoints Patrik Frisk as COO
- Osiris Therapeutics appoints Linda Palczuk as CEO
- Host Hotels & Resorts appoints Mary Hogan Preusse to board
- McCormick & Company appoints Tony Vernon to board
- Intrexon appoints Mark Carnegie-Brown as Oxitec CEO
More inside POST
AB Inbev to buy soft drinks firm Hiball Companies
Blackrock Q2 income rises 8% Earnings